Fairmount Funds Management LLC - 17 Aug 2022 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
Director, Other*, 10%+ Owner
Signature
/s/ Chris W. Trester, Attorney-in-fact for Fairmount Funds Management LLC
Issuer symbol
VRDN
Transactions as of
17 Aug 2022
Net transactions value
+$9,999,978
Form type
4
Filing time
19 Aug 2022, 16:32:21 UTC
Previous filing
21 Jun 2022
Next filing
13 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRDN Common Stock Purchase $9,999,978 +425,531 +45% $23.50 1,363,764 17 Aug 2022 Fairmount Healthcare Fund II LP F2
holding VRDN Common Stock 5,859 17 Aug 2022 Fairmount Healthcare Fund LP F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fairmount Funds Management LLC and Fairmount Healthcare Fund GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund LP ("Fund I"). They disclaim beneficial ownership of securities held by Fund I for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
F2 Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC have voting power and investment power over the shares of Common Stock and Series A Non-Voting Convertible Preferred Stock held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.

Remarks:

The Reporting Persons may each be deemed a director by deputization of Issuer by virtue of the fact that each of Peter Harwin and Tomas Kiselak serve on the board of directors of Issuer and are also each a Managing Member of Fairmount Funds Management LLC.